on October 7, 2004
Published online before print October 7, 2004, doi: 10.1161/01.ATV.0000147534.69062.dc
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on July 12, 2004
Accepted on September 23, 2004
Potential Role of Endotoxin as a Proinflammatory Mediator of Atherosclerosis
Lynn L. Stoll *;
From the Department of Internal Medicine, Divisions of Cardiovascular Diseases (L.L.S., N.L.W.) and Infectious Diseases (G.M.D.), University of Iowa and The VA Medical Center, Iowa City, Iowa.
* To whom correspondence should be addressed. E-mail: stolll{at}mail.medicine.uiowa.edu.
Abstract--Atherosclerosis is increasingly recognized as a chronic inflammatory disease. Although a variety of inflammatory markers (ie, C-reactive protein) have been associated with atherosclerosis and its consequences, it is important to identify principal mediators of the inflammatory responses. One potentially important source of vascular inflammation in atherosclerosis is bacterial endotoxin. Mutations in Toll-like receptor 4 (TLR-4), an integral component of the endotoxin signaling complex, are fairly common in the white population and have recently been associated with reduced incidence of atherosclerosis and other cardiovascular diseases in some studies. Moreover, epidemiological studies suggest that endotoxemia at levels as low as 50 pg/mL constitutes a strong risk factor for the development of atherosclerosis. Endotoxin concentrations in this range may be produced by a variety of common subclinical Gram-negative infections. In this article, we outline the main elements of the endotoxin signaling receptor complex that initiates proinflammatory signaling (lipopolysaccharide binding protein, CD14, TLR-4, and MD-2) and discuss how changes in expression of these molecules may affect proatherogenic responses in the vessel wall. We also describe some of the proinflammatory effects of endotoxin that may be relevant to atherosclerosis, and discuss how serum lipoproteins, especially high-density lipoprotein, may modulate endotoxin-induced inflammatory responses. Further, we discuss recent findings suggesting that the lipid-lowering statins may have an additional protective role in blocking at least some of these proinflammatory signaling pathways. Finally, we discuss species diversity with regard to endotoxin signaling that should be considered when extrapolating experimental data from animal models to humans.
This article has been cited by other articles:
 |
|
 |
|
  H. Ghanim, P. Mohanty, R. Deopurkar, C. Ling Sia, K. Korzeniewski, S. Abuaysheh, A. Chaudhuri, and P. Dandona Acute Modulation of Toll-Like Receptors by Insulin Diabetes Care, September 1, 2008; 31(9): 1827 - 1831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.A. E. Kallio, K. Buhlin, M. Jauhiainen, R. Keva, A. M. Tuomainen, B. Klinge, A. Gustafsson, and P. J. Pussinen Lipopolysaccharide associates with pro-atherogenic lipoproteins in periodontitis patients Innate Immunity, August 1, 2008; 14(4): 247 - 253. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Malarstig, S. Sigurdsson, P. Eriksson, G. Paulsson-Berne, U. Hedin, L. Wallentin, A. Siegbahn, A. Hamsten, and A.-C. Syvanen Variants of the Interferon Regulatory Factor 5 Gene Regulate Expression of IRF5 mRNA in Atherosclerotic Tissue But Are Not Associated With Myocardial Infarction Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 975 - 982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-C. Szeto, B. C.-H. Kwan, K.-M. Chow, K.-B. Lai, K.-Y. Chung, C.-B. Leung, and P. K.-T. Li Endotoxemia is Related to Systemic Inflammation and Atherosclerosis in Peritoneal Dialysis Patients Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 431 - 436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Erridge, T. Attina, C. M Spickett, and D. J Webb A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1286 - 1292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rajesh, P. Mukhopadhyay, S. Batkai, G. Hasko, L. Liaudet, J. W. Huffman, A. Csiszar, Z. Ungvari, K. Mackie, S. Chatterjee, et al. CB2-receptor stimulation attenuates TNF-{alpha}-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2210 - H2218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sandbo, S. Taurin, D. M. Yau, S. Kregel, R. Mitchell, and N. O. Dulin Downregulation of smooth muscle {alpha}-actin expression by bacterial lipopolysaccharide Cardiovasc Res, May 1, 2007; 74(2): 262 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Frolov and D. Y. Hui The Modern Art of Atherosclerosis: A Picture of Colorful Plants, Cholesterol, and Inflammation Arterioscler. Thromb. Vasc. Biol., March 1, 2007; 27(3): 450 - 452. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Suzuki, E. Bayna, H. L. Li, E. D. Molle, and W. Y.W. Lew Lipopolysaccharide Activates Calcineurin in Ventricular Myocytes J. Am. Coll. Cardiol., January 30, 2007; 49(4): 491 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jayachandran, G. J. Brunn, K. Karnicki, R. S. Miller, W. G. Owen, and V. M. Miller In vivo effects of lipopolysaccharide and TLR4 on platelet production and activity: implications for thrombotic risk J Appl Physiol, January 1, 2007; 102(1): 429 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Erridge, C. M. Spickett, and D. J. Webb Non-enterobacterial endotoxins stimulate human coronary artery but not venous endothelial cell activation via Toll-like receptor 2 Cardiovasc Res, January 1, 2007; 73(1): 181 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Li and B. Frei Iron Chelation Inhibits NF-{kappa}B-Mediated Adhesion Molecule Expression by Inhibiting p22phox Protein Expression and NADPH Oxidase Activity Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2638 - 2643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Mohammad, M. Morran, B. Slotterbeck, D. W. Leaman, Y. Sun, H. v. Grafenstein, S.-C. Hong, and M. F. McInerney Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse Int. Immunol., July 1, 2006; 18(7): 1101 - 1113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Doherty, P. K. Shah, M. Arditi, L. L. Stoll, G. M. Denning, and N. L. Weintraub Lipopolysaccharide, Toll-Like Receptors, and the Immune Contribution to Atherosclerosis Arterioscler. Thromb. Vasc. Biol., May 1, 2005; 25(5): e38 - e39. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Warnholtz, S. Genth-Zotz, and T. Munzel Should Treatment of Sepsis Include Statins? Circulation, April 12, 2005; 111(14): 1735 - 1737. [Full Text] [PDF]
|
|